Tactile Systems Technology(US:TCMD)2025-05-05 20:26Company Overview - The company focuses on revealing and treating patients with underserved chronic conditions in the home, including lymphedema and bronchiectasis[4] - The total addressable market (TAM) for these conditions is estimated to be over $10 billion[4] - In 2024, the company served over 79,000 patients[4] Financial Performance (2024) - Total revenue for 2024 was $293.0 million[4] - Gross margin for 2024 was 74.0%[4] - Adjusted EBITDA for 2024 was $37.1 million[4] - Operating cash flow for 2024 was $40.7 million[4] Market Opportunity - Approximately 2.5 million patients are diagnosed with lymphedema and bronchiectasis, while an estimated 25 million remain undiagnosed[4] - The company estimates a $5 billion+ addressable market for lymphedema and another $5 billion+ for bronchiectasis[32] Key Strategies - The company aims to increase access to care, expand treatment options, enhance lifetime patient value, and improve patient experience[70] - A key focus is on removing existing barriers to care through market development, clinical evidence generation, and payer advocacy[70]